It's taken 30 years, but GlaxoSmithKline's experimental malaria vaccine is finally ready for regulatory review. Looking to bring the world's first shot for the mosquito-borne disease to market, the pharma giant said Thursday that it has submitted its candidate for approval.
The discovery of vials of "variola," commonly known as smallpox, in a storage room at the National Institutes of Health in Bethesda, MD, has raised new concerns that the virus could be used in a bioterrorism attack.
International debate is brewing over whether to give experimental vaccines to people in regions of the current Ebola outbreak in West Africa in an effort to thwart the spread of the deadly virus.
After hitting its primary endpoint in a Phase II study last fall, Agenus was already leading a Sanofi-NIH collaboration in efforts to develop the first genital herpes vaccine. Now, it's built on that lead with new Phase II results for its therapeutic candidate, HerpV, which achieved statistical significance in reducing viral load.
Chikungunya fever is a dangerous tropical virus that has recently surfaced in the U.S. after erupting in the Caribbean. But Austria-based Themis Bioscience may eventually have a way to combat it, new data suggest.
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.
Two doses of the oral cholera vaccine Shanchol provided an 86% percent protection rate during a recent outbreak in Guinea, according to a new study.
Virulent flu strains pose the danger of potential release, even when used in experiments for vaccine research, and investigators from the Harvard and Yale universities are calling for greater scrutiny of such studies.
Polio is on the rise in Pakistan, in part because of fears that Western vaccine workers there could be doubling as spies. But according to the CIA, that should no longer be a concern.
BOSTON-- Sanofi's Phase II trial results for its Clostridium difficile vaccine are proof that the French drug giant is leading the race for preventive therapies for the deadly bacterial infection.